None of the 29 investors followed here reported a position in TKNO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TKNO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 5, 2026 | Gunstream StephenChief Executive Officer | Purchase at price 2.15 per share. | 26K | $55.80K |
| Mar 5, 2026 | Lowell MatthewChief Financial Officer | Purchase at price 2.19 per share. | 40K | $87.62K |
| Jun 26, 2025 | Demski Martha J.Director | Sale at price 5.06 per share. | 8K | $40.51K |
| Jun 16, 2025 | Demski Martha J.Director | Stock Award(Grant) at price 0.00 per share. | 54.3K | — |
| Jun 16, 2025 | Robertson Brett MDirector | Stock Award(Grant) at price 0.00 per share. | 54.3K | — |
| Jun 16, 2025 | Vos AlexanderDirector | Stock Award(Grant) at price 0.00 per share. | 54.3K | — |
| Jun 16, 2025 | Vos AlexanderDirector | Stock Award(Grant) at price 0.00 per share. | 54.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -36.3 | 6.6 | 12.0 | 22.8 | 52.1 | 5.2 | -12.0 | 43.6 | 24.0 | -7.6 | +116.3% | ||
| 2025 | 5.9 | -26.5 | -20.2 | 28.5 | -13.5 | -14.9 | -7.9 | -4.4 | 43.3 | -15.2 | -10.9 | -18.8 | −54.5% |
| 2024 | -13.9 | -10.6 | -7.7 | -32.8 | -1.1 | -22.2 | 174.5 | 31.4 | -2.0 | 40.5 | 9.9 | 11.8 | +123.9% |
| 2023 | 5.7 | -9.1 | -45.4 | -36.1 | 103.2 | -30.5 | 27.0 | -42.5 | 43.1 | -28.7 | 2.5 | 82.8 | −33.9% |
| 2022 | -22.9 | 7.7 | -18.8 | -18.7 | -31.9 | 9.8 | -22.7 | -30.5 | -25.9 | 37.4 | 2.8 | 19.5 | −72.5% |
| 2021 | -6.4 | -14.4 | 30.9 | -7.6 | -2.7 | -8.4 | −13.7% |
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Buy / hold / sell counts